Cargando…

1 Ultra-Rush Specific Immune Therapy with Depigmented and Polymerized Allergen Extracts is Effective and Safe in Patients With Severe SAR Highly Sensitized against Pollen Allergens

BACKGROUND: Procedures for specific immune therapy (SIT) vary widely. We were interested whether a pre-seasonal ultra-rush treatment with depigmented and polymerized allergen extracts is effective and safe in patients with severe SAR. METHODS: 31 pts (21 f, 10 m, mean age 39.7 years, range: 17–69 ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruber, Michaela, Amon, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization Journal 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513123/
http://dx.doi.org/10.1097/01.WOX.0000411746.36918.a8
_version_ 1782251881149497344
author Gruber, Michaela
Amon, Ulrich
author_facet Gruber, Michaela
Amon, Ulrich
author_sort Gruber, Michaela
collection PubMed
description BACKGROUND: Procedures for specific immune therapy (SIT) vary widely. We were interested whether a pre-seasonal ultra-rush treatment with depigmented and polymerized allergen extracts is effective and safe in patients with severe SAR. METHODS: 31 pts (21 f, 10 m, mean age 39.7 years, range: 17–69 years) with severe SAR and partial asthma attacks (31.3%) during pollen season (mean total IgE level 152 kU/L, range: 5–5113 kU/L; mean Phadia CAP class 3.7 and 3.5 against birch pollen and Bet v1, resp.; mean Phadia CAP class 3.7 and 3.3 against grass pollen and Phl p1,5, resp.) were treated with an ultra-rush schedule receiving the maximum dose of 0.2 plus 0.3 mL of a allergen extract (DepiQuick, Novartis, Germany) on day one, followed by further injecting the maximum dose of 0.5 mL at weekly intervals for 5 weeks. Patients were interviewed by a questionnaire 2 months after the pollen season. RESULTS: 75.8% of patients reported a good or very good effect of SIT with respect to their symptoms during the pollen season after having received only one cycle of ultra-rush SIT; 18.4 did not notice any effect after the first cycle; one patient reported an increase of symptoms. 56.5% of patients did use less anti-allergic medication in comparison with their mean need before SIT; in 18.8% the need of medication was comparable to the year before. In 77.8% of all cases ultra-rush SIT was well tolerated subjectively. Local swelling at the injection site was reported in 25.9% (immediate) and 42.4% (delayed); 4 patients felt a mild discomfort after injection with pruritus, fatigue, or dizziness, respectively. The systemic symptoms disappeared spontaneously without medication. CONCLUSIONS: Even for patients with clinically severe SAR and high specific sensitization against birch or grass pollen the pre-seasonal ultra-rush SIT regimen with depigmented, polymerized allergen extracts showed a good efficacy and tolerability.
format Online
Article
Text
id pubmed-3513123
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher World Allergy Organization Journal
record_format MEDLINE/PubMed
spelling pubmed-35131232012-12-21 1 Ultra-Rush Specific Immune Therapy with Depigmented and Polymerized Allergen Extracts is Effective and Safe in Patients With Severe SAR Highly Sensitized against Pollen Allergens Gruber, Michaela Amon, Ulrich World Allergy Organ J Abstracts of the XXII World Allergy Congress BACKGROUND: Procedures for specific immune therapy (SIT) vary widely. We were interested whether a pre-seasonal ultra-rush treatment with depigmented and polymerized allergen extracts is effective and safe in patients with severe SAR. METHODS: 31 pts (21 f, 10 m, mean age 39.7 years, range: 17–69 years) with severe SAR and partial asthma attacks (31.3%) during pollen season (mean total IgE level 152 kU/L, range: 5–5113 kU/L; mean Phadia CAP class 3.7 and 3.5 against birch pollen and Bet v1, resp.; mean Phadia CAP class 3.7 and 3.3 against grass pollen and Phl p1,5, resp.) were treated with an ultra-rush schedule receiving the maximum dose of 0.2 plus 0.3 mL of a allergen extract (DepiQuick, Novartis, Germany) on day one, followed by further injecting the maximum dose of 0.5 mL at weekly intervals for 5 weeks. Patients were interviewed by a questionnaire 2 months after the pollen season. RESULTS: 75.8% of patients reported a good or very good effect of SIT with respect to their symptoms during the pollen season after having received only one cycle of ultra-rush SIT; 18.4 did not notice any effect after the first cycle; one patient reported an increase of symptoms. 56.5% of patients did use less anti-allergic medication in comparison with their mean need before SIT; in 18.8% the need of medication was comparable to the year before. In 77.8% of all cases ultra-rush SIT was well tolerated subjectively. Local swelling at the injection site was reported in 25.9% (immediate) and 42.4% (delayed); 4 patients felt a mild discomfort after injection with pruritus, fatigue, or dizziness, respectively. The systemic symptoms disappeared spontaneously without medication. CONCLUSIONS: Even for patients with clinically severe SAR and high specific sensitization against birch or grass pollen the pre-seasonal ultra-rush SIT regimen with depigmented, polymerized allergen extracts showed a good efficacy and tolerability. World Allergy Organization Journal 2012-02-17 /pmc/articles/PMC3513123/ http://dx.doi.org/10.1097/01.WOX.0000411746.36918.a8 Text en Copyright © 2012 by World Allergy Organization
spellingShingle Abstracts of the XXII World Allergy Congress
Gruber, Michaela
Amon, Ulrich
1 Ultra-Rush Specific Immune Therapy with Depigmented and Polymerized Allergen Extracts is Effective and Safe in Patients With Severe SAR Highly Sensitized against Pollen Allergens
title 1 Ultra-Rush Specific Immune Therapy with Depigmented and Polymerized Allergen Extracts is Effective and Safe in Patients With Severe SAR Highly Sensitized against Pollen Allergens
title_full 1 Ultra-Rush Specific Immune Therapy with Depigmented and Polymerized Allergen Extracts is Effective and Safe in Patients With Severe SAR Highly Sensitized against Pollen Allergens
title_fullStr 1 Ultra-Rush Specific Immune Therapy with Depigmented and Polymerized Allergen Extracts is Effective and Safe in Patients With Severe SAR Highly Sensitized against Pollen Allergens
title_full_unstemmed 1 Ultra-Rush Specific Immune Therapy with Depigmented and Polymerized Allergen Extracts is Effective and Safe in Patients With Severe SAR Highly Sensitized against Pollen Allergens
title_short 1 Ultra-Rush Specific Immune Therapy with Depigmented and Polymerized Allergen Extracts is Effective and Safe in Patients With Severe SAR Highly Sensitized against Pollen Allergens
title_sort 1 ultra-rush specific immune therapy with depigmented and polymerized allergen extracts is effective and safe in patients with severe sar highly sensitized against pollen allergens
topic Abstracts of the XXII World Allergy Congress
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513123/
http://dx.doi.org/10.1097/01.WOX.0000411746.36918.a8
work_keys_str_mv AT grubermichaela 1ultrarushspecificimmunetherapywithdepigmentedandpolymerizedallergenextractsiseffectiveandsafeinpatientswithseveresarhighlysensitizedagainstpollenallergens
AT amonulrich 1ultrarushspecificimmunetherapywithdepigmentedandpolymerizedallergenextractsiseffectiveandsafeinpatientswithseveresarhighlysensitizedagainstpollenallergens